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Abstract
Background: Xenograft samples used to test anti-cancer drug efficacies and toxicities in vivo contain an unknown
mix of mouse and human cells. Evaluation of drug activity can be confounded by samples containing large
amounts of contaminating mouse tissue. We have developed a real-time quantitative polymerase chain reaction
(qPCR) assay using TaqMan technology to quantify the amount of mouse tissue that is incorporated into human
xenograft samples.
Results: The forward and reverse primers bind to the same DNA sequence in the human and the mouse genome.
Using a set of specially designed fluorescent probes provides species specificity. The linearity and sensitivity of the
assay is evaluated using serial dilutions of single species and heterogeneous DNA mixtures. We examined many
xenograft samples at various in vivo passages, finding a wide variety of human:mouse DNA ratios. This variation
may be influenced by tumor type, number of serial passages in vivo, and even which part of the tumor was
collected and used in the assay.
Conclusions: This novel assay provides an accurate quantitative assessment of human and mouse content in
xenograft tumors. This assay can be performed on aberrantly behaving human xenografts, samples used in
bioinformatics studies, and periodically for tumor tissue frequently grown by serial passage in vivo.
Background
Human xenografts implanted and grown in immunode-
ficient mice are commonly used to expand tumor cell
populations for cancer stem cell investigations [1] and
to test anti-cancer drug efficacies or toxicities in vivo
[2]. It is often assumed any anti-tumor drug activity is
due to targeting pathways in the human cells present in
the xenograft, and any associated gene expression data
is derived from a mostly human cell population. How-
ever, as the implanted xenograft grows in the mouse its
human stromal cells are replaced by mouse stromal cells
[3], influencing its microenvironment and resulting in a
tumor xenograft that is a heterogeneous mixture of
human and mouse derived cell populations. Each cell
type may possess different growth rates and react differ-
ently to an administered drug. Further, there are many
reliable reports in the literature of human xenografts
serially passed in vivo transforming adjacent mouse cells
into fibrosarcoma-like malignancies [4-8]. Drugs tested
on such samples would generate false and misleading
data. How can researchers easily verify that a tumor
xenograft sample contains only a relatively small num-
ber of contaminating mouse cells?
Over the years, several groups have attempted to
answer this question using in situ hybridization [9,10] or
immunohistochemical procedures [11]. However, they
are slow, labor-intensive endeavors, and are limited by
subjective, difficult-to-reproduce measurements.
Recently, PCR-based strategies have been developed
which take advantage of the ability of species-specific
oligomer primers to quickly amplify species-specific
genomic DNA sequences. Ono et al [12] were able to
differentiate fourteen different species by targeting their
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DNA sequences. Cooper et al [13] took this a step
further by performing fourteen species-specific PCR
reactions simultaneously in a single PCR tube ("multi-
plexing”). Each species-specific amplicon was a unique
length, different enough fro mt h eo t h e r st ob es u c c e s s -
fully resolved on a 4% agarose gel. While these methods
are certainly not quantitative, they are fast, easy, and
accurate. One way to obtain a more quantitative result
is to take advantage of DNA sequencing technology to
measure gene length variation by PCR-amplification of
several markers across different chromosomes then
compare the species-specific differences in relative
amplicon lengths [14]. This improved method still
requires manually measuring peak heights generated by
capillary electrophoresis from an ABI 3100 Genetic
Analyzer, a robust but still expensive and uncommon
piece of laboratory equipment. This method also relies
on the use of multiple genomic loci, many of which are
located on or near chromosomal regions known to be
deleted or amplified in some human cancers.
Real-Time Quantitative PCR (qPCR) instruments have
been used to quantify genomic DNA from multiple spe-
cies in mixed DNA samples: multiple human targets
[15]; rhesus and long-tailed macaques [16]; feline,
bovine, equine, and cervid [17]; human, cat, and dog
[18]. These machines have become commonplace and a
96-well plate can be processed in 90 minutes or less.
Therefore, we set out to develop a multiplex qPCR
assay that addresses some of the obstacles that limited
previous methodologies. Herein we describe the assay
methodology, various quality control analyses, and a sur-
vey of human xenograft samples to illustrate the kind of
real-world results that can be expected from the assay.
Results and Discussion
Initial sequence targeting and validation
We surveyed information from several published reports
[19-22] to help identify a chromosomal region that is
not known to be frequently duplicated/deleted in
human disease or near a recombination hotspot, yet
very homologous to the orthologous mouse sequence.
The prostaglandin E receptor 2 (PTGER2)g e n er e g i o n
on human chromosome 14q22 fits these guidelines. We
focused on a target region within that gene which has
high homology between human and mouse sequences
allowing us to design primers which could bind both
sequences equally well and amplify the homologous
sequences (see Figure 1A). For the species-specific quali-
tative PCR, we designed species-specific forward primers
which contain seven non-homologous base pairs (listed
in Figure 1B). Along with the common reverse primer,
the species specificity of these primers is illustrated in
Figure 2A, where the human-specific forward primer
generates a 189 bp band only in samples that are
human-only or from xenografts known to contain
human material. Similarly in Figure 2B, the mouse-spe-
cific forward primer generates the 189 bp band only in
samples derived from mouse tissues, mouse-tumor allo-
grafts, or human xenografts which invariably contain
some mouse tissue. This qualitative, end-point PCR
assay can be used to quickly screen xenograft samples
to verify the presence of human DNA and confirm that
a xenograft has not been replaced by a mouse-only
fibrosarcoma.
The real-time qPCR assay was designed to estimate
the percentage of human and mouse DNA contained in
a xenograft or other mixed-DNA sample. The human
+mouse forward and common reverse primers were
designed to bind the same PTGER sequences on human
a n dm o u s eg e n o m i cD N A( F i g u r e1 A ,B ) .T h e ya m p l i f y
the same 215 bp DNA sequence, whether the template
DNA is from mouse or human sources, minimizing dif-
ferences in amplification efficiency and primer-binding.
Two species-specific Taqman probes, each conjugated
with a unique fluorescent tag, were designed to target a
non-homologous sequence within the amplified region
(Figure 1C). These species-specific probes allow for mul-
tiplex reaction chemistry in a single PCR reaction tube,
minimizing pipetting error and maximizing the number
of samples that can be tested on a single 96-well optical
plate. All qPCR data in this manuscript were derived
using the probes as described in Figure 1. However, we
have also tested the probe sequences with flip-r fluoro-
phores (Human-VIC and Mouse-NED) with no loss of
qPCR efficiency or species specificity. To verify the spe-
cies-specificity of the real-time qPCR assay, we set up
reactions containing a known quantity of single species
DNA sample along with both qPCR primers and both
qPCR probes. Serial dilutions were used to investigate
the assay sensitivity and reliability. Figure 3 shows the
resulting qPCR traces and the resulting standard curve
comparing mean CT to log initial genomes using either
the human prostate carcinoma cell line LNCaP or the
mouse B16F10 melanoma tumor DNA. As expected, the
graphs illustrating the use of human probe + human
primers (Figure 3A) or mouse probe + mouse primers
(Figure 3E) both show robust sequence amplification
from approximately 30,000 down to 2 initial genomes.
But the mouse probe does not bind to the amplified
human sequence (Figure 3B), and the human probe
does not bind to the amplifiedm o u s es e q u e n c e( F i g u r e
3D), thus confirming the assay’s species specificity.
Although the variance in CTs increases dramatically
when testing the lowest starting DNA amounts (10 gen-
omes or less), the mean CT is still on the linear stan-
dard curve down to approximately 2 haploid genomes
in both species (Figure 3C and 3F).
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Next, we evaluated the assay using samples containing
known amounts of human and mouse DNA at inverse
proportions serially diluted such that the total amount
of DNA in each sample was 100 ng (Figure 4A). Total
genomes of each species were calculated from the
known DNA concentrations. Samples were run in tripli-
cate and the mean CTs and standard deviations (SD)
are listed in Figure 4A. SDs less than 0.5 are considered
acceptable. Genome numbers were calculated as before
and converted to “percentage human” and “percentage
mouse”. These results were compared to the initial
number of human genomes in Figure 4B and percent of
initial mouse genomes in Figure 4C. There is a linear
correlation for both species with R
2 = 0.998.
In reality, the ratio of human and mouse DNA in a given
xenograft or other mixed DNA sample is initially
unknown. We can verify the robustness of the qPCR assay
by comparing the initial amount of template DNA in a
given sample to the sum of the mass of the measured
number of human and mouse genomes. We surveyed 22
human xenograft samples, currently being grown in our
facility, comprising different tumor types and various
lengths of serial passage in vivo (Table 1). The average
percentage of mouse contamination in the tumor xeno-
grafts varies widely from 0% (undetectable under current
assay conditions) to 87% in MDA-MB-361. Low mouse
contamination percentages were found in all in vivo pas-
sages, from P1 to P10, and high mouse contamination was
found in some P1 passage xenografts, suggesting the
length of time spent in vivo is not a significant factor in
predicting which xenografts will contain the highest
amount of contaminating mouse cells. There was signifi-
cant variability amongst samples of the same tumor type,
as illustrated in the five LOX IMVI tumor samples. Mouse
contamination varied in these from 45%-66%, even though
PCR Oligo Primers
Species Forward Primer  Common Reverse Primer          Amplicon (bp)
Human gctgcttctcattgtctcgg gccaggagaatgaggtggtc 189
Mouse cctgctgcttatcgtggctg same reverse primer listed above  189
Human + Mouse  tacctgcagctgtacgccac  same reverse primer listed above  215
Real-Time qPCR Probes
Species Fluorophore  Sequence  Quencher
Human NED  tgctgcttctcattgtctcg MGBNFQ
Mouse VIC  cctgctgcttatcgtggctgM G B N F Q
A
B
C
Human PTGER2
Mouse PTGER2
Human + Mouse
Forward primer
Human PTGER2
Mouse PTGER2
Human PTGER2
Mouse PTGER2
Common Reverse
primer
Figure 1 Relevant species alignment using the PTGER2 gene and the PCR primers and real-time qPCR probe sequences derived from
the alignment. A) The human and mouse PTGER2 DNA sequences are aligned, with red letters signifying non-conserved basepairs. Human
+Mouse PCR primers are listed underneath, and a black bar is below the qPCR probe sequence. The reverse-compliment Common Reverse
primer sequence is shown to illustrate alignment on the DNA strand shown. B) Qualitative PCR primers are listed, as well as the expected size of
the amplified sequence. All sequences listed 5’ to 3’. Mouse genome specific base pairs are underlined in the mouse forward primer and mouse
probe sequences. C) Real-time qPCR probe sequences are listed next to their fluorophore and quencher.
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tant factors that may contribute to the amount of mouse
contamination in a xenograft may include the histological
type of tumor, how many times it was serially passaged in
vivo and how vascularized the xenograft normally
becomes. Additional sample collection and analysis is
required to investigate this further. The mass of measured
human and mouse DNA in each sample can be summed
and compared to the initial amount of DNA; the percen-
tage of measured/initial DNA is shown in the far right col-
u m ni nT a b l e1 .T h i sd a t as e tw a sg e n e r a t e db yt w o
operators each performing the assay multiple times thus
some variance is expected. We routinely find that the per-
cent human and percent mouse measurements are robust
from assay to assay, but pipetting variations contribute to
the variation in magnitude of the calculated species DNA
and adds greatly to the variance sometimes seen in the %
of initial DNA calculation. Using only one operator greatly
reduces this variance. We have designed this qPCR assay
for a 20 μl reaction volume solely as a cost-saving mea-
sure. However, using the standard 50 μl qPCR reaction
volumes reduces the impact of variations in pipetting and
may be preferable for some operators.
Conclusions
This qPCR method allows for quick and accurate esti-
mations of mouse contamination in human xenografts.
This is important when accessing anti-tumor drug effi-
cacy in human tumor xenografts and in evaluating any
other mixed DNA sample where significant proportions
of mouse DNA could influence the interpretation of the
results.
Methods
Cell lines and xenografts
Human cancer cell lines were obtained from ATCC/
LGC (Wesel, Germany) or the DCTD Repository (Fre-
derick, MD) and were cultured in RPMI Medium 1640
(Life Technologies, Carlsbad, CA) supplemented with
10% fetal calf serum and 2 mM L-glutamine. All cell
lines were maintained in a humidified incubator at 37°C
i nt h ep r e s e n c eo f5 %C O 2. Human xenograft samples
were implanted subcutaneous in athymic nude mice
(Balb/c nu/nu, 4-6 weeks old), which were purchased
from Charles River Laboratories (Frederick, MD) and
maintained under sterile and controlled conditions of
temperature (22-24C), light (12-h light/12-h dark), and
humidity (45-65%), with food and water ad libitum.
Xenografts used for this study were routinely harvested
when they reached 500 mg in size, before a necrotic
c o r ed e v e l o p s ,a n da f t e r1 ,4 ,o r1 0s e r i a li nv i v op a s -
sages. Each of the fresh tumors harvested for DNA
extraction were divided using surgical scissors into mul-
tiple fragments of similar size (~150 mg), each contain-
ing regions from both the tumor’s core and periphery.
DNA extraction and purification
Tissues and cell lines were processed using a modified
version of the REDExtract-N-Amp Tissue PCR kit pro-
tocol (Sigma-Aldrich, St. Louis, MO). Briefly, samples
(~150 mg wet weight) were incubated overnight in a
mixture of 100 μL extraction buffer, 10 μL tissue pre-
paration solution, and 5 μLo f1 0m g / m lp r o t e i n a s eK
(Life Technologies) at 50°C in a slowly rotating rotisserie
oven. Samples were neutralized the next morning by
adding 110 μL neutralization buffer and 5 μL 20 mg/mL
Purelink RNase-A (Life Technologies), followed by incu-
bations at 37°C and 96°C for 15 minutes each. To quan-
tify DNA for real-time qPCR assays, genomic DNA was
purified with the standard phenol-chloroform method
and resuspended in 10 mM Tris-Cl buffer, pH 8.0, or
diluted in distilled, sterile water. DNA concentrations
were measured on a NanoDrop-1000 (Thermo Fisher
Scientific, Inc., Waltham, MA).
Qualitative, end-point PCR
Unique human and mouse-specific primer pairs,
designed using Primer3 software [23]http://frodo.wi.mit.
edu/primer3/, rely on species-specific differences
(underlined in Figure 1b) in the forward primers to
amplify 189 bp fragments of the prostaglandin E
Figure 2 Species specificity of the qualitative PCR primers.
Panel A was generated using the human-forward and common
reverse primers listed in Figure 1B. Only samples containing human
cells show the human 189 bp band. Panel B uses the mouse-
forward and common reverse primers listed in Figure 1B. Only
samples containing genomic mouse DNA show the expected
mouse amplicon. As expected, the serially passaged xenograft
samples show the presence of both human and mouse DNA, as
early as the first in vivo passage (X) and even after ten in vivo serial
passages (lanes X1 and X2). Acronyms: M231 (MDA-MB-231 human
breast cancer cells), H92 (HOP-92 human lung cancer cells), LNCaP
(LNCaP human prostate cancer cells), ntc (no template control), Kid
(kidney), Spl (spleen), B16 (B16F10 mouse melanoma tumor), C26
(Colon-26 mouse colon tumor), M435 (MDA-MB-435 human
melanoma), A375 (human malignant melanoma), C (cultured cell
line), X (xenograft, harvested after one passage in vivo), X1 and X2
(xenograft, harvested after ten serial passages in vivo), bp (base
pairs).
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Page 4 of 8receptor 2 (PTGER2) gene. PCR primers were purchased
from Applied Biosystems (ABI) by Life Technologies.
PCR was performed using neutralized but unpurified tis-
sue/cell lysate on an ABI-2720 Thermocycler (Life
Technologies). PCR conditions: 95°C-5 min, 30 cycles of
(94°C-45 sec, 60°C-30 sec, 72°C-90 sec), 72°C-10 min.
DNA bands were resolved on a 2% agarose gel + ethi-
dium bromide (0.5 μg/ml).
Figure 3 Representative example of real-time qPCR fluorescent signal traces (ΔRn vs cycles) showing species specificity of the qPCR
probes and a species-specific standard curve derived from each data set. A) The human probe shows robust DNA amplification signals in
samples consisting of only LNCaP human prostate carcinoma cell line template DNA. B) In the same LNCaP samples, the mouse probe shows no
binding or product amplification. C) Plotting mean CT (+/- SD) vs log human genomes initially present in the qPCR reaction tube, the serial
dilution from (A) is linear down to 1.8 human haploid genomes. D) The human-specific probe does not bind to B16F10 mouse melanoma tumor
template DNA. E) The mouse-specific probe does show amplification when using B16F10 mouse tumor DNA as a template. F) A standard curve
derived from the mean mouse probe CT signal plotted against log mouse genomes present in (E) shows a linear correlation down to 2 initial
genomes.
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The qPCR primers and probes were designed using Pri-
mer3 software [23] (http://frodo.wi.mit.edu/primer3/)
and purchased from ABI (Life Technologies). Target
sequences represent regions located in the human and
mouse prostaglandin E receptor 2 (PTGER2) genes (see
Figure 1A). Real-time qPCR was carried out on an ABI-
7500 Real Time PCR System (Applied Biosystems) using
custom-labelled species-specific probes (ABI) according
to the manufacturer’s protocol with 50 ng of total geno-
mic DNA (unless otherwise specified) in 20 μLr e a c t i o n
volumes. The qPCR conditions were as follows: 50°C-2
min, 95°C-10 min, 40 cycles of (95°C-15 sec, 60°C-1
min). The human+mouse forward primer and the com-
mon reverse primer listed in Figure 1B were added to
each qPCR reaction tube to obtain the same final con-
centrations (200 nM). Both probes (Figure 1C) were also
added to each reaction tube for a final concentration of
200 nM. Samples were usually run in triplicate on the
same reaction plate. Samples were assayed on at least
three different 96-well reaction plates, often by two dif-
ferent operators, before statistical analysis was per-
formed. All ΔRn thresholds were calculated by default
from the 7500 ABI software, v 2.0.5.
Data analysis and statistics
Each qPCR reaction plate requires the presence of the
standard curve samples, which contain serial dilutions of
mouse-only, human-only, or human+mouse mixed sam-
ples of known DNA concentration. Standard curves
were developed in Microsoft Excel (Microsoft, Red-
mond, WA) by graphing the mean Threshold Cycle
(CT) on the y-axis versus the log initial genomes on the
x-axis. A linear trend line was generated, with the
Figure 4 Example of a serial dilution study to verify linearity in mixed DNA samples. A) Each sample contains 100 ng total DNA,
composed of various ratios of mouse kidney and human MDA-MB-435 melanoma cell line DNA in regular 10 ng increments. The corresponding
numbers of initial haploid genomes are calculated, and the mean CT and SD from the qPCR results for reach probe are listed. B) Plotting the
measured number of human genomes (y-axis) versus the known number of initial human genomes present in each sample (x-axis) yields a
linear curve (blue line) with R
2 = 0.998. C) Similarly, plotting the measured number of mouse genomes versus the initial number of mouse
genomes yields a linear curve with R
2 = 0.998.
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from Mean CT values. “Percent mouse” was estimated
by dividing the number of mouse genomes by the sum
of both human plus mouse genomes, multiplied by 100.
“Percent human” was calculated similarly. The measured
genome number was used to back-calculate the mea-
sured mass of each species DNA by applying the follow-
ing equation to each [24]
M=N g × 1.096e−21g/bp
where M = mass of the haploid genome (in grams), Ng
= number of base pairs (bp) in haploid genome, and g =
grams. The mouse genome is estimated to be 2.651 bil-
lion bp (as of NCBI genome Build 36.1), while the
human genome is estimated to be 3.038 billion bp (as of
NCBI genome Build 36.3). Thus, one haploid mouse
genome is approximately 2.9 pg, whereas one human
haploid genome is approximately 3.33 pg.
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Table 1 Species quantification results from a survey of selected xenografts.
Xenograft
Name
Tumor
Type
in vivo
Passage
Initial DNA
(ng)
Average %
Human ± SD
Average
%
Mouse
Calculated
Human
DNA
Calculated
Mouse
DNA
Sum DNA
(ng)
% of Initial
DNA
HL-60(TB) Leukemia P01 27.6 100.0 ± 0.00 0.0 26.96 0.00 27.0 97.7
MDA-MB-361 Breast P01 48.8 12.8 ± 1.84 87.2 4.80 31.20 36.0 73.7
NCI-H157 Lung P01 72.4 98.9 ± 1.50 1.1 97.83 1.29 99.1 136.8
RXF-631 Renal P01 23.2 43.2 ± 0.06 56.8 9.90 11.34 21.2 91.5
SK-MEL-2 Melanoma P01 29.2 81.8 ± 1.42 18.2 38.63 7.66 46.3 158.4
UACC-257 Melanoma P01 53.7 99.9 ± 0.08 0.1 49.49 0.04 49.5 92.3
LOX IMVI Melanoma P01-a 50.6 48.4 ± 7.26 51.6 16.15 17.54 33.7 66.6
LOX IMVI Melanoma P01-b 52.8 55.1 ± 6.38 45.0 19.30 16.77 36.1 68.3
LOX IMVI Melanoma P01-c 55.5 39.6 ± 7.99 60.4 17.13 27.34 44.5 80.2
LOX IMVI Melanoma P01-d 52.1 53.1 ± 6.56 46.9 24.81 35.35 60.2 115.4
LOX IMVI Melanoma P01-e 53.5 33.9 ± 7.76 66.1 20.15 45.56 65.7 122.9
AS283 Lymphoma P04-a 56.9 83.5 ± 5.89 16.5 37.12 7.39 44.5 78.3
AS283 Lymphoma P04-b 71.6 83.6 ± 4.90 16.4 86.85 13.31 100.2 139.8
CA46 Lymphoma P04 43.4 99.9 ± 0.09 0.1 47.76 0.04 47.8 110.2
CP70 Ovarian P04 61.4 83.5 ± 3.23 16.6 59.56 9.87 69.4 113.0
Daudi Lymphoma P04 56.5 100.0 ± 0.02 0.0 49.03 0.01 49.0 86.7
GTL-16 Gastric P04 42.3 100.0 ± 0.00 0.0 39.92 0.00 39.9 94.4
OVCAR-5 Ovarian P04 53 88.8 ± 0.31 11.2 63.11 6.98 70.1 132.1
AS283 Lymphoma P10 49.2 99.3 ± 0.82 0.7 48.04 0.22 48.3 98.1
HuH-7 Liver P10 55.2 90.1 ± 4.26 9.9 52.24 4.36 56.6 102.5
NCI-H1975-
Luc-GFP
Lung P10 56.4 34.9 ± 6.18 65.1 18.67 29.45 48.1 85.4
NCI-H209-Luc-
GFP
Lung P10 61.7 81.0 ± 2.00 19.0 79.70 15.83 95.5 154.8
The xenograft names, tumor types, and number of in vivo passages a sample has progressed through are given for each sample at the time of sample collection.
Letters following the passage number signify independent tumor samples derived from tumors grown on different mice of the same cohort. After DNA
extraction and purification, samples were diluted between 25 ng/μl and 75 ng/μl; one microliter of this dilution serves as the initial DNA (ng) template in the
qPCR reactions. The CT value for each sample was derived from standard curves and converted to a log genomes value, which can be converted to the number
of measured haploid genomes present. Percent Human and Percent Mouse values were derived by dividing # human genomes by total genomes present or #
mouse genomes divided by total genomes present, respectively. Genome numbers for each species are back-calculated into DNA (ng), the sum of which should
be equal to the initial DNA used in the qPCR sample. The far right column lists the percentage of the initial sample calculated from the qPCR assay and gives a
measure of quality assurance.
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